TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03884036

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamine D

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamine D
Study: NCT02063269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: 9-18mg/rivastigmine for 52 weeks
Study: NCT03473197

Intervention type: DRUG
Group type: OTHER
Intervention: Diacerein 1% ointment
Description: During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
Study: NCT00267670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg PO TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill PO TID
Study: NCT04919161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight support system control group
Description: The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body weight support system with balance perturbations
Description: The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress.
Study: NCT04408079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3558
Description: TQB3558 is a kinase inhibitor of the TRK protein family.
Study: NCT03295916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
Study: NCT02362451

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologus elutriated monocyte placebo vaccine
Description: 20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Description: 20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Description: 20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
Study: NCT02476162

Intervention type: DEVICE
Intervention: iHealth Wireless Blood Pressure Monitor
Description: Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening.

Intervention type: DEVICE
Intervention: iHealth Wireless Blood Pressure Monitor
Description: Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening.

Intervention type: DEVICE
Intervention: iHealth Wireless Blood Pressure Monitor
Description: Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening.
Study: NCT01245751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
Study: NCT02648906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00620542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: capsule, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: capsule, oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: capsule, oral, one daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: capsule, oral, one daily
Study: NCT05104346

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: appendectomy
Description: open or laparoscopic appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: open or laparoscopic appendectomy
Study: NCT03573856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Living
Description: Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health and Safety
Description: Participants will be provided with education related to general health and safety topics.
Study: NCT01319968

Intervention type: DRUG
Intervention: Estriol 0.1% vaginal cream
Description: Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
Study: NCT02980796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice
Description: Each experimental day participants will complete a session of skilled motor practice.
Study: NCT00198120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: same dosing schedule and capsule strength
Study: NCT01073475

Intervention type: OTHER
Intervention: There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
Description: There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses.

Intervention type: OTHER
Intervention: There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
Description: There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses.
Study: NCT04553315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest expansion exercises
Description: Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest expansion exercises
Description: Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
Study: NCT03213236

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Homemonitoring diagnostic system
Description: In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram.
Study: NCT01348698

Intervention type: PROCEDURE
Intervention: Tumor tissue biopsy
Description: Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.

Intervention type: PROCEDURE
Intervention: Surgery
Description: Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
Study: NCT02388009

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexyn2a
Description: Intramuscular doses of 0.5 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular doses of 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexyn2a plus adjuvant
Description: Intramuscular doses of 0.5 mL
Study: NCT03853928

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII).
Study: NCT03423472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake
Description: Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake
Description: Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Baby Toolkit
Description: The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army
Study: NCT03035539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study: NCT04172272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic multimodal analgesia administered intravenously
Description: Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP block)
Description: The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously
Description: TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
Study: NCT03399292

Intervention type: DRUG
Intervention: Cationorm MD sine eye drops
Description: studyparticipants receive lipidbased eye drops once only in the study eye

Intervention type: DRUG
Intervention: Cationorm MD sine eye drops
Description: studyparticipants receive lipidbased eye drops once only in the study eye

Intervention type: DRUG
Intervention: Cationorm MD sine eye drops
Description: studyparticipants receive lipidbased eye drops once only in the study eye

Intervention type: DRUG
Intervention: Cationorm MD sine eye drops
Description: studyparticipants receive lipidbased eye drops once only in the study eye
Study: NCT00820534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penciclovir
Description: Penciclovir every 2 hours during waking hours for 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 2 hous during waking hours for 96 hours
Study: NCT02600793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
Study: NCT03831997

Intervention type: DRUG
Intervention: Dextrose 5% W/ Sodium Chloride 0.225%
Description: D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
Study: NCT00886236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Study: NCT02980796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice
Description: Each experimental day participants will complete a session of skilled motor practice.
Study: NCT01525771

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Docetaxel
Description: The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days
Study: NCT03253822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
Study: NCT01230008

Intervention type: RADIATION
Intervention: no drugs
Description: Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
Study: NCT03647007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11 for health
Description: The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
Study: NCT00683995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246 (fentanyl citrate)
Study: NCT01091207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The patients will receive daily oral administration of sorafenib 400 mg twice daily.
Study: NCT03186365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zepatier Oral Product
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier Oral Product
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks